Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
IL3RA
REST API REST API
Homo sapiens
IL3RA is differentially expressed in 187 experiments: 71 organism parts: lung, blood, ... (69 more);, 118 disease states: normal, lung adenocarcinoma, ... (116 more);, 70 cell types 156 cell lines 17 compound treatments and 59 other conditions.
Synonyms CD123
Orthologs Csf2ra (Mus musculus)   ENSGALG00000019148 (Gallus gallus)   ENSGALG00000019147 (Gallus gallus)   ENSGALG00000016693 (Gallus gallus)   IL3RA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, receptor activity, integral to membrane, interleukin-3 receptor activity
InterPro Term IL6_recept-bd
UniProt Accession P26951, Q9UEH7
Search EB-eye ENSG00000185291
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-GEOD-6573, E-MEXP-1251, E-MTAB-24, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-22639, E-GEOD-19639, E-GEOD-2450, E-GEOD-24147, E-GEOD-19480, ... (21 experiments)

Factor Value U/D Experiments
MCF-7
2
 E-GEOD-20081, E-GEOD-5823
WIDR
1
 E-MTAB-37
CESS
1
 E-MTAB-37
ChaGoK1
1
 E-MTAB-37
UACC893
1
 E-MTAB-37
NCIH1666
1
 E-MTAB-37
150 more value(s).


Cell type

studied in E-MEXP-1242, E-GEOD-22373, E-GEOD-3920, E-MEXP-66, E-GEOD-360, ... (43 experiments)

Factor Value U/D Experiments
plasma cell
2
 E-MEXP-2360, E-GEOD-6691
721 B lymphoblast
2
 E-AFMX-5, E-TABM-145
CD34+
2
 E-AFMX-5, E-TABM-145
monocyte
2
3
 E-GEOD-5099, E-MEXP-583, E-GEOD-11755, E-GEOD-7307, E-GEOD-22373 ... (5 experiments)
secretory cell
1
 E-GEOD-3998
whole blood
1
 E-GEOD-3026
64 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1869, E-GEOD-1577, ... (34 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
 E-MTAB-37, E-MTAB-62, E-GEOD-2514, E-MEXP-231
AIDS-KS, HIV+, nodular (late) stage
2
 E-MTAB-62, E-MEXP-66
emphysema
1
 E-MTAB-62
thyroid carcinoma
1
 E-MTAB-37
lung atypical carcinoid tumor
1
 E-MTAB-37
synovial sarcoma
1
 E-GEOD-6481
112 more value(s).


Compound treatment

studied in E-MEXP-1269, E-GEOD-5258, E-GEOD-3284, E-GEOD-412, E-GEOD-2803, ... (12 experiments)

Factor Value U/D Experiments
estradiol
1
 E-GEOD-20081
5-aza-2'-deoxycytidine
2
1
 E-MEXP-1269
M-CSF
1
 E-GEOD-5099
bacterial endotoxin
1
 E-GEOD-3284
granulocyte macrophage-colony stimulating factor
1
 E-GEOD-2803
lipopolysaccharide
1
 E-MEXP-1958
11 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
 E-GEOD-19519
tunicamycin
1
 E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-TABM-125, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-MTAB-37, E-MEXP-1251, E-GEOD-1563, E-GEOD-16363, E-GEOD-21340 ... (5 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-MEXP-2359, E-GEOD-3891, E-MEXP-2283, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-MTAB-69, E-GEOD-3013

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-361

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-21750, E-GEOD-3624, E-GEOD-17347, ... (6 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, E-MEXP-2146 ... (5 experiments)

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-GEOD-16363, ... (25 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004, E-LGCL-5

Phenotype
studied in E-GEOD-1493, E-GEOD-21750

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Vehicle
studied in E-GEOD-5258

Processing time: 0.416 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM